Lagis Enterprise Co., Ltd.
TTPEX:673031.80
TWD
-0.95
(-2.90%)
ISIN
TW0006730005
Return %
Stock
S&P 500
1Y
-32.05
14.20
3Y
-15.31
81.12
5Y
5.30
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Cheng Hsiung Chen
- Full Time Employees
- 238
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No.29, Gong 1st Road Taichung TX Taiwan 437101
- IPO Date
- Nov 8, 2019
- Website
- lagis.com.tw
- Similar Companies
- Business
- Lagis Enterprise Co., Ltd. specializes in the development and manufacturing of minimally invasive surgical instruments and devices. The company's core product portfolio includes laparoscopic consumables, endoscopic instruments, trocar systems, single-port access devices, bipolar forceps, suction irrigation systems, specimen retrieval bags, wound protectors, and gynecological surgical instruments such as uterine manipulators and advanced single-port devices for vNOTES (vaginal natural orifice transluminal endoscopic surgery). Lagis operates with a strong focus on medical equipment manufacturing, targeting surgical and healthcare providers across more than 50 countries globally, including Asia, America, Europe, Oceania, and Africa. Founded in 2004 and headquartered in Taichung, Taiwan, Lagis is recognized as Asia's leading MDR qualification brand with products made in Taiwan that emphasize high precision and durability. Recently, Lagis has significantly expanded its production capacity by completing a second factory facility in Taiwan, which is three times larger than its original plant and is currently undergoing GMP certification. The company has strengthened its position in the minimally invasive surgical device market by leveraging advanced automation in production to optimize quality and efficiency. Lagis maintains a strategic emphasis on innovation in robotic surgery applications, notably enhancing its suction irrigation system with FDA 510(k) clearance for improved performance in such surgeries. The company also continues to promote partnerships and participate in international medical expos to bolster its global footprint and customer reach in the healthcare sector. These operational expansions and product advancements mark key developments for Lagis in the last 1-2 years, reinforcing its leadership in minimally invasive surgical solutions. Lagis Enterprise Co., Ltd. reports consistent financial performance backed by a diversified portfolio, reinforcing its strategic focus on expanding minimally invasive surgical devices and enhancing manufacturing capacities to meet growing global demand. The company remains privately held with ongoing commitments to research, development, and automation technology in surgical instruments manufacturing. This comprehensive profile reflects Lagis Enterprise's position as a specialized medical device manufacturer delivering advanced laparoscopic and endoscopic solutions worldwide with recent expansions and innovations to support surgical precision and patient outcomes.